Has the U.S. Biotech Industry valuation changed over the past few years?

Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 7.0x is lower than the industry's current PS ratio of 8.6x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 21 Aug 2026	US$1.5t	US$173.1b	-US$20,935,348,834.41	17.8x	-71x	8.6x
Sun, 19 Jul 2026	US$1.4t	US$169.2b	-US$12,119,559,510.09	17.3x	-115.3x	8.3x
Tue, 16 Jun 2026	US$1.3t	US$170.0b	-US$12,162,265,505.10	16.4x	-105.5x	7.5x
Thu, 14 May 2026	US$1.3t	US$171.7b	-US$11,491,259,456.48	17.2x	-115x	7.7x
Sat, 11 Apr 2026	US$1.3t	US$166.2b	-US$11,949,463,221.18	17.5x	-109.2x	7.9x
Mon, 09 Mar 2026	US$1.3t	US$169.6b	-US$14,215,772,987.80	21x	-91.5x	7.7x
Wed, 04 Feb 2026	US$1.3t	US$163.6b	-US$15,053,781,146.73	20.6x	-84.4x	7.8x
Fri, 02 Jan 2026	US$1.2t	US$163.5b	-US$15,348,052,088.89	21.3x	-79x	7.4x
Sun, 30 Nov 2025	US$1.2t	US$163.6b	-US$16,204,135,751.28	19x	-77.1x	7.6x
Tue, 28 Oct 2025	US$1.2t	US$163.4b	-US$18,535,387,674.19	17.8x	-62.8x	7.1x
Thu, 25 Sep 2025	US$1.1t	US$163.5b	-US$18,318,414,671.61	16.5x	-59.2x	6.6x
Sat, 23 Aug 2025	US$1.1t	US$163.6b	-US$18,600,438,658.14	15.1x	-57.7x	6.6x
Mon, 21 Jul 2025	US$961.3b	US$155.2b	-US$23,259,963,048.32	16.5x	-41.3x	6.2x
Wed, 18 Jun 2025	US$940.7b	US$155.9b	-US$23,954,335,834.04	17.1x	-39.3x	6x
Fri, 16 May 2025	US$863.7b	US$155.9b	-US$24,603,386,779.22	14.7x	-35.1x	5.5x
Sun, 13 Apr 2025	US$740.4b	US$119.2b	-US$36,465,001,079.34	19.8x	-20.3x	6.2x
Tue, 11 Mar 2025	US$845.2b	US$118.7b	-US$37,516,362,615.25	18.1x	-22.5x	7.1x
Thu, 06 Feb 2025	US$852.4b	US$117.2b	-US$30,787,020,617.09	17.5x	-27.7x	7.3x
Sat, 04 Jan 2025	US$971.4b	US$149.6b	-US$26,354,792,434.12	17x	-36.9x	6.5x
Mon, 02 Dec 2024	US$1.0t	US$150.0b	-US$26,595,044,865.34	16.4x	-39.2x	6.9x
Wed, 30 Oct 2024	US$898.1b	US$113.4b	-US$36,099,862,624.13	20.1x	-24.9x	7.9x
Fri, 27 Sep 2024	US$885.6b	US$113.2b	-US$36,051,039,342.95	21.4x	-24.6x	7.8x
Sun, 25 Aug 2024	US$908.6b	US$113.2b	-US$35,874,993,723.21	23.6x	-25.3x	8x
Tue, 23 Jul 2024	US$1.2t	US$164.5b	-US$28,074,139,763.44	29.1x	-42.5x	7.3x
Thu, 20 Jun 2024	US$1.1t	US$164.4b	-US$27,969,500,563.98	27.2x	-40.6x	6.9x
Sat, 18 May 2024	US$1.1t	US$164.6b	-US$26,831,179,712.66	23.9x	-42.7x	7x
Mon, 15 Apr 2024	US$1.1t	US$164.3b	-US$23,399,427,407.87	21.1x	-46.9x	6.7x
Wed, 13 Mar 2024	US$1.2t	US$167.3b	-US$22,031,216,768.79	18.8x	-54.1x	7.1x
Fri, 09 Feb 2024	US$1.2t	US$169.3b	-US$26,196,624,627.91	19.6x	-44x	6.8x
Sun, 07 Jan 2024	US$1.4t	US$204.8b	-US$22,501,061,722.00	20.5x	-63.1x	6.9x
Tue, 05 Dec 2023	US$1.3t	US$204.7b	-US$22,047,091,184.00	19x	-57.3x	6.2x
Thu, 02 Nov 2023	US$1.2t	US$207.6b	-US$15,463,681,135.00	16.9x	-77.5x	5.8x
Sat, 30 Sep 2023	US$1.3t	US$207.4b	-US$12,733,898,979.00	17.1x	-99.6x	6.1x
Mon, 28 Aug 2023	US$1.3t	US$207.6b	-US$12,455,656,838.00	17.5x	-102.5x	6.1x


US Market	-0.79%
Healthcare	3.62%
Biotech	6.17%
Biotech	6.17%

Company	Last Price	7D	1Y	Valuation
MRNA Moderna	US$133.31	109.4% +US$27.8b	408.4%	PS23.9x
ABBV AbbVie	US$261.83	4.4% +US$19.5b	25.0%	PE73.8x
AMGN Amgen	US$433.82	3.8% +US$8.6b	46.7%	PE26.8x
GILD Gilead Sciences	US$143.45	3.8% +US$6.6b	23.5%	PS5.8x
VRTX Vertex Pharmaceuticals	US$540.26	4.6% +US$6.0b	35.9%	PE31.1x

Announcement • 6h

Regeneron Pharmaceuticals Announces FDA Approval for Pasatru to Reduce Formation of New Heterotopic Ossification Lesions and Clinician-Assessed Flare-Ups in Adults with Fibrodysplasia Ossificans Progressiva

Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Pasatru can be administered across a range of care settings, including home infusion where appropriate. The recommended starting dosage is based on weight at 10 mg/kg and is given intravenously over 60 minutes once monthly (every four weeks) but may be decreased to a 3 mg/kg infusion over 60 minutes once monthly if not tolerated. Pasatru is a VelocImmune®-derived, fully human monoclonal antibody that blocks Activin A, a protein that Regeneron scientists discovered to be critical in the development of HO lesions in people with FOP. Pasatru was granted approval based on efficacy and safety data from the positive Phase 3 OPTIMA trial evaluating Pasatru in adults with FOP. At 56 weeks, both doses of Pasatru, 10 mg/kg (n=23) and 3 mg/kg (n=19), met the primary endpoint and were highly efficacious in reducing the total number of new HO lesions as compared to placebo (n=21), demonstrating a 90% (2 lesions vs. 19 lesions) and 94% (1 lesion vs. 19 lesions) reduction, respectively, as assessed by computed tomography (CT) scan. The number of clinician-assessed flare-ups during this time, a key secondary endpoint, were 9 for Pasatru 10 mg/kg (88% reduction compared to placebo), 53 for Pasatru 3 mg/kg (15% reduction compared to placebo), and 66 for placebo. Changes in the proportion of patients with patient-reported flare-ups through week 56 were not significantly different between placebo and Pasatru treatment groups. At 56 weeks, among all 63 people who participated in the trial, serious treatment-emergent adverse events occurred in 2 patients treated with 10 mg/kg Pasatru, 1 patient treated with 3 mg/kg Pasatru, and 2 patients treated with placebo. The most common adverse reactions occurring in =10% of adults with FOP treated with Pasatru 10 mg/kg or 3 mg/kg were abscess, acne, increased hair growth, madarosis (loss of eyebrows), oral ulcers, epistaxis (nosebleeds), folliculitis, paronychia (nail infection), and rash. Pasatru was granted approval based on efficacy and safety data from the positive Phase 3 OPTIMA trial evaluating Pasatru in adults with FOP. OPTIMA is a Phase 3, multi-center, multinational trial to assess the efficacy of Pasatru on the reduction of heterotopic bone formation and flares, as well as its safety, tolerability, and pharmacokinetics, in patients with active FOP. The trial enrolled 63 participants aged 18 years and older who have any FOP-causing variant of type I Activin A receptor (ACVR1), exhibited FOP disease activity or progression of HO lesions, and had a cumulative analogue joint involvement scale (CAJIS) score at screening of =19. CAJIS is a scoring tool used by clinicians to assess the degree of joint involvement, with higher scores representing a greater degree of disease severity (scale: 0 to 30). Eligible participants were randomized to receive intravenously administered Pasatru 10 mg/kg, Pasatru 3 mg/kg, or placebo once every four weeks for 56 weeks. Following this, participants could elect to then continue their originally assigned treatment in a double-blind extension phase for at least 84 weeks or discontinue treatment and enter an observation-only arm. During the treatment period, efficacy was evaluated through whole body CT scans for HO lesions, physician and patient assessment of flare-ups, utilization of CAJIS to rate joint functionality, and observances of change in disease severity. Safety assessment includes reports of adverse events, measurement of vital signs, physical examination, and coagulation testing. A Phase 3 trial of Pasatru in adolescents and children with FOP, OPTIMA 2, is planned to begin later this year. Pasatru is a VelocImmune-derived, fully human monoclonal antibody that binds and neutralizes Activin A, which is involved in the development of heterotopic bone in people with FOP. PASATRU can cause serious side effects, including harm to your unborn baby including serious birth defects if taken during pregnancy. Females who are pregnant must not take PASATRU. Females who can become pregnant: Your healthcare provider will ask you to take a pregnancy test to verify that you are not pregnant before starting treatment with PASATRU. Use effective birth control (contraception) during treatment with PASATRU and for 6 months after the last dose of PASATRU. If you become pregnant or think you may be pregnant during treatment with PASATRU, stop taking PASATRU immediately and call your healthcare provider right away. Infections of the skin and tissue under the skin requiring treatment or hospitalization, such as infected lumps (abscesses) and bacterial skin infections (cellulitis), may happen while you are taking PASATRU. Call your healthcare provider right away if you have signs or symptoms of skin infection, such as pain or tenderness, redness, fever, skin feels warm to the touch, feeling generally unwell, swelling. Nosebleeds (epistaxis) including serious nosebleeds that require medical care, can happen while taking PASATRU. Tell your healthcare provider right away if you have a nosebleed that is severe or heavy, does not stop with basic first-aid measures, such as pinching your nose with continuous firm pressure, lasts more than 20 minutes. Do not receive PASATRU if you are pregnant. Before you receive PASATRU, tell your healthcare provider about all your medical conditions, including if you are breastfeeding. It is not known whether PASATRU passes into your breastmilk. Breastfeeding is not recommended during treatment with PASATRU and for 6 months after the last dose of PASATRU. Talk to your healthcare provider about the best way to feed your baby during this time. Are concerned about male fertility. PASATRU may affect your ability to father a child. Talk to your healthcare provider if this is concern for you. Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effects of PASATRU include infected lumps (abscess), hair loss of eyebrows or lashes (madarosis), acne, increased hair growth, mouth sores (oral ulcers), nosebleeds (epistaxis). These are not all of the possible side effects of PASATRU. PASATRU™ (garetosmab-grts) is a prescription medicine used to reduce the formation of new abnormal bone growth outside of the skeleton (heterotopic ossification) and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). It is not known if PASATRU is safe and effective in children.

U.S. Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Regeneron Pharmaceuticals Announces FDA Approval for Pasatru to Reduce Formation of New Heterotopic Ossification Lesions and Clinician-Assessed Flare-Ups in Adults with Fibrodysplasia Ossificans Progressiva

Merck & Co., Inc. And Moderna, Inc. Announce Phase 3 INTerpath-001 Trial Of Intismeran Autogene Plus KEYTRUDA Met Endpoints Of Recurrence-Free Survival And Distant Metastasis-Free Survival In Patients With Completely Resected Stage IIB-IV Melanoma

Insider recently sold US$825k worth of stock

Insider exercised options and sold US$5.6m worth of stock

ALKS: Orexin Pipeline Data Will Drive Future Upside Potential

VRTX: Kidney And Endocrine Expansion Will Drive Future Stock Upside

BNTX: PD L1 VEGF Oncology Readouts Will Determine Future Upside Potential

Insider notifies of intention to sell stock

Independent Director recently sold US$641k worth of stock

Summit Therapeutics and Arcus Launch Major Renal Cancer Trial with Ivonescimab Combination

Consensus revenue estimates decrease by 18%, EPS upgraded

Erasca Advances ERAS-0015 Toward Registration Trials After Strong Pancreatic Cancer Results

Hemab Therapeutics Unveils New Clinical Data and Confirms Phase 3 Trial Timeline

Consensus revenue estimates increase by 29%, EPS downgraded

INSM: Respiratory Franchise Execution Will Outweigh Index Removal And Launch Concerns